NUHY | PHYD | NUHY / PHYD | |
Gain YTD | 5.224 | 4.696 | 111% |
Net Assets | 94.5M | 205M | 46% |
Total Expense Ratio | 0.31 | 0.58 | 53% |
Turnover | 43.00 | 36.00 | 119% |
Yield | 6.44 | 6.32 | 102% |
Fund Existence | 6 years | 2 years | - |
NUHY | PHYD | |
---|---|---|
RSI ODDS (%) | 1 day ago43% | 1 day ago23% |
Stochastic ODDS (%) | 1 day ago67% | 1 day ago18% |
Momentum ODDS (%) | 1 day ago45% | 1 day ago61% |
MACD ODDS (%) | 1 day ago46% | 1 day ago42% |
TrendWeek ODDS (%) | 1 day ago56% | 1 day ago56% |
TrendMonth ODDS (%) | 1 day ago51% | 1 day ago50% |
Advances ODDS (%) | 1 day ago59% | 1 day ago53% |
Declines ODDS (%) | 11 days ago48% | 8 days ago30% |
BollingerBands ODDS (%) | 1 day ago44% | 1 day ago26% |
Aroon ODDS (%) | 1 day ago52% | 1 day ago51% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
WSCGX | 34.92 | 0.42 | +1.22% |
Allspring Small Company Growth Inst | |||
HGOTX | 77.86 | 0.64 | +0.83% |
Hartford Growth Opportunities R5 | |||
MGFRX | 9.54 | 0.06 | +0.63% |
MassMutual Global R4 | |||
MUEAX | 37.98 | 0.19 | +0.50% |
MFS Blended Research Core Equity A | |||
SHPAX | 18.81 | -0.19 | -1.00% |
Saratoga Health & Biotechnology A |
A.I.dvisor tells us that PHYD and EQT have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHYD and EQT's prices will move in lockstep.
Ticker / NAME | Correlation To PHYD | 1D Price Change % | ||
---|---|---|---|---|
PHYD | 100% | +0.21% | ||
EQT - PHYD | 7% Poorly correlated | -0.73% | ||
OMF - PHYD | 6% Poorly correlated | +0.54% | ||
AR - PHYD | -1% Poorly correlated | +0.61% |